CGEN - Compugen Ltd. Price to Earnings Adjusted for Growth Rate

Compugen Ltd. (CGEN) is scaling its AI-driven antibody R&D platform, monetizing patents through licensing agreements with pharma behemoths. The PEG ratio helps assess the premium paid for the company's future success, with the latest parameter standing at 0.00. While the business focuses on identifying new targets for immune activation, it remains critically dependent on external CRO and CMO contractors.

Compugen Ltd. is optimizing expenses by monetizing its oncology developments through strategic alliances and licensing agreements with pharmaceutical behemoths. An analysis of the PEG ratio allows for a comparison of the current P/E market multiple with the rate of earnings expansion, where a value below one signals that the asset is undervalued relative to its growth rates, confirming the long-term investment attractiveness of the business.